PL EN


Preferences help
enabled [disable] Abstract
Number of results
2008 | 49 | 2 | 201-203
Article title

Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene

Title variants
Languages of publication
EN
Abstracts
EN
Point mutations of bcr-abl tyrosine kinase are the most frequent causes of imatinib resistance in chronic myeloid leukaemia (CML) patients. In most CML cases with BCR-ABL mutations leading to imatinib resistance the second generation of tyrosine kinase inhibitors (TKI- e.g. nilotinib or dasatinib) may be effective. Here, we report a case of a CML patient who during imatinib treatment did not obtain clinical and cytogenetic response within 12 months of therapy. The sequencing of BCR-ABL kinase domains was performed and revealed the presence of a F359I point mutation (TTC-to-ATC nucleotide change leading to Phe-to-Ile amino acid substitution). After 1 month of nilotinib therapy a rapid progression of clinical symptoms was observed. In the presence of the F359I point mutation only dasatinib treatment overcame imatinib and nilotinib resistance.
Discipline
Publisher

Year
Volume
49
Issue
2
Pages
201-203
Physical description
Contributors
author
author
author
author
author
References
Document Type
ARTICLE
Publication order reference
Marta Baranska, Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60?569 Poznan, Poland
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-400371fb-8088-3f9c-9f47-439cf11882e1
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.